Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A lot of large reported trades after cop. Hard to work out if they're buys or sells without the actual times of trades.
I'm looking hard at this one. Might jump in tomorrow. Can see a bit of upside here. Ste
Any one buying in??
MIDAS SHARE TIPS: Tate & Lyle faces healthier future - thanks to new low sugar diet By JOANNE HART, FINANCIAL MAIL ON SUNDAY PUBLISHED: 22:02, 5 December 2015
Maybe lunch to follow !
I stand corrected two cups of coffee and a danish now !
No comments for some time , am I the only holder left standing . I am shocked I am actually back in profit ! Can only afford one coffee though
Answer my own question. Just seen that the update is now due tomorrow, which is probably why the SP has dropped over the last 2 days. Would be good to get a positive report and one which gives investors confidence for the next 6 months
What happened to the trading statement due on 2nd October 2015? Is it no news is good news?
Hi Mistermister Tate are actually moving out of Sugar and into specialist sweeteners, additives etc so NOT so reliant on the Sugar price as once was. They have been digging in, cost cutting and diversifying for the last 3 years. I honestly think they have stabalized and bottomed out share price wise and would now seem to be a good income play......good luck lummox
If the price of sugar was to rise would this be good or bad for this company? Im not sure if they buy their sugar or produce it their-self
29 Sep 2015 Tate & Lyle PLC TATE Liberum Capital Buy 586.00 581.50 670.00 670.00 Reiterates SP Target 670p
Nice, found a site that gives forward earnings and Fundies right up to 2018 Financial Ratios Size 2016e 2017e Capitalization 2 572 M GBP - Entreprise Value (EV) 3 070 M GBP 3 083 M GBP Valuation 2016e 2017e P/E ratio (Price / EPS) 16,2x 15,4x Capitalization / Revenue 1,00x 0,99x EV / Revenue 1,20x 1,19x EV / EBITDA 9,21x 8,74x Yield (DPS / Price) 5,08% 5,18% Price to book (Price / BVPS) 2,72x 2,21x Profitability 2016e 2017e Operating Margin (EBIT / Sales) 8,89% 9,50% operating Leverage (Delta EBIT / Delta Sales) -1,61x 6,66x Net Margin (Net Profit / Revenue) 6,42% 6,84% ROA (Net Profit / Asset) 8,47% 8,63% ROE (Net Profit / Equities) 15,4% 15,9% Rate of Dividend 82,4% 79,8% Balance Sheet Analysis 2016e 2017e CAPEX / Sales 7,88% 4,87% Cash Flow / Sales (Taux d'autofinancement) 9,62% 9,86% Capital Intensity (Assets / Sales) 0,76x 0,79x Financial Leverage (Net Debt / EBITDA) 1,49x 1,45x Annual Income Statement Data Actuals in M GBP Estimates in M GBP Fiscal Period March 2013 2014 2015 2016 2017 2018 Sales 3 256 3 147 2 694 2 567 2 599 2 648 Operating income (EBITDA) 449 457 351 334 353 373 Operating profit (EBIT) 358 349 247 228 247 261 Pre-Tax Profit (EBT) 309 290 51,0 209 227 244 Net income 278 245 30,0 165 178 191 P/E ratio - - - 16,2 15,4 14,0 EPS (PNC) 58,5 52,1 6,50 34,0 35,8 39,5 Dividend per Share (PNC) 26,2 27,6 28,0 28,0 28,6 29,3 Yield 4,75% 5,00% 5,08% 5,08% 5,18% 5,31% Announcement Date 05/30/2013 06:00am 05/29/2014 06:00am 05/28/2015 06:52am - - -
Tate & Lyle PLC (OTCMKTS:TATYY) was upgraded by Liberum Capital to a “buy” rating in a note issued to investors on Thursday, Marketbeat.com reports. Several other brokerages also recently weighed in on TATYY. Goldman Sachs raised shares of Tate & Lyle PLC from a “sell” rating to a “neutral” rating in a research note on Tuesday, July 21st. Societe Generale raised shares of Tate & Lyle PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 30th. Citigroup Inc. reissued a “neutral” rating on shares of Tate & Lyle PLC in a research note on Monday. Zacks upgraded shares of Tate & Lyle PLC from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Numis Securities Ltd upgraded shares of Tate & Lyle PLC from a “reduce” rating to a “hold” rating in a report on Thursday, June 4th. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Tate & Lyle PLC presently has an average rating of “Buy” and a consensus price target of $38.00. Tate & Lyle PLC (OTCMKTS:TATYY) opened at 33.575 on Thursday. Tate & Lyle PLC has a 12 month low of $31.04 and a 12 month high of $41.41. The stock has a 50 day moving average price of $33.51 and a 200 day moving average price of $34.94. The stock has a market capitalization of $3.89 billion and a P/E ratio of 83.938. Tate & Lyle PLC is a provider of ingredients and solutions to the food, beverage and other industries. The Company uses technologyto turn raw materials into ingredients for its customers. These ingredients add taste, texture, nutrition and increased functionality to products. Its customers include industrial, animal feed, pharmaceutical and personal care markets. The Company operates in two segments namely Speciality Food Ingredients (OTCMKTS:TATYY) and Bulk Ingredients (BI). In SFI segment, the Company operates three categories: sweeteners, such as SPLENDA Sucralose and crystalline fructose; texturants, such as starch and gums; and wellness ingredients, such as PROMITOR dietary fibres, PromOat Beta Glucan and SODA-LO Salt Microspheres. BI manufactures and markets products including liquid sweeteners (corn syrup, dextrose and glucose), industrial starches, citric acid, bio fuels, and animal feed including corn gluten feed and corn gluten meal.
Purchased Tate & Lyle some while ago as a ' good prospect ' for my income ISA. Now just about level after a rough few months. Considering the market of late T & L has been very positive and resilient even before these latest broker updates. Perhaps it has at last levelled out and back on the way up. Anyway the near 5% dividend seems to offer good support ?
<b>Tate & Lyle tops FTSE 100 on Liberum upgrade Thu 24 September 2015 10:22 | A A A</b> (ShareCast News) - Tate & Lyle was the standout gainer on the FTSE 100 after Liberum upgraded the stock to 'buy' from 'sell' and lifted its price target to 670p from 505p. Register for Tate & Lyle plc share research updates "While history is disappointing - four profit warnings and a collapse of around 40% in pre-tax profits since full-year 2014 - we see early signs of change and scope for significant upside," it said. The brokerage said full-year 2016 will prove an inflection point and forecasts a 16% rebound in full-year 2017 pre-tax profit as one-off items drop out and new Speciality Food Ingredients capacity comes online. Liberum said the key question is whether management's strategy can deliver visible, sustainable earnings growth beyond FY17. In order to determine the potential, it benchmarked Tate's operations with US-based Ingredion, which is the group's closest peer. It said the results are reassuring. "As we suspected, many facets of Tate's operations compare favourably to Ingredion. In our view, Tate's historical difficulties are grounded in execution and strategic ambition, areas that management is working to address." It added that the company's commitment to a flat dividend in full-year 2016 implies a 5% yield which appears sufficient to support the shares buying time for management to turn around the business and work towards executing the group's long-term strategy. At 1028 BST, Tate shares were up 2.6% at 566p.
TATE Tate @ Lyle PLC Looks like a recovery going on here at TATE. I hear the sugar market as recovered in favour of the manufacturer. I have been long for a few days, best to time your entry according to your trading/investment style. Broker upgrades this morning.......... 24 Sep 2015 Tate & Lyle PLC TATE Liberum Capital Buy 562.75 551.50 505.00 670.00 Upgrades SP Target 670p http://content.screencast.com/users/mickkipper/folders/Default/media/491949c5-00db-4ddf-b22e-2f5abae0f6bf/Tate%201.jpg
28 Aug 2015 Tate & Lyle PLC TATE Canaccord Genuity Buy 536.50 502.00 - 685.00 Reiterates SP Target 685p.
Tate & Lyle PLC (TATE:LSE): Last: 519.00, up 17 (+3.39%), High: 526.50, Low: 518.00, Volume: 982.90k BE Deboo at Jefferies turns buyer. BE Growing signals of improving CWM economics lead us to upgrade numbers, and view. The ’16 HFCS pricing round in the US has started early and robustly: a sign of confidence. Experience shows that HFCS is a barometer of wider SFI & Bulk economics and that when the cycle turns, it can do so quickly, and dramatically. With the shares visiting 500p and yielding 5.6%, we turn positive. Opening shots in the pricing round signal confidence…and rising margins. Reports indicate that pricing letters on HFCS for 2016 have been published – the earliest we can remember. Millers are asking for a 15-20% hike, in a climate of flat to falling corn costs. This signals healthily tight utilisation. It may not conclude quite this well, but it doesn’t need to, to sweeten Tate’s bottom line very nicely. BE Benefits Bulk directly, but a positive signal on SFI, too. We obsess on HFCS, unapologetically, not just because it’s now c.40% of profits but also because it’s a visible signal of the wider health of US Corn Wet Milling (CWM), which will account for over 80% of profits following the exit from Europe. There is strong correlation between Tate’s profits in SFI and Bulk and between both and HFCS margins. Complications: tolling, ethanol & Sucralose. 75% of Tate’s HFCS is on de-risked tolling contracts, which moderates any upside, and they are still brewing 40m gallons of (unprofitable) ethanol. Yesterday’s acquisition of Splenda by Heartland might impact tabletop Sucralose volumes. So we skip the final couple of turns of our pencil sharpener. BE Q1 body language positive. Chairman Buying. We’ve been quiet since the Q1. Worth remembering, then, that ‘body language’ on the call – on Sucralose, Allulose, and life generally – was notably more positive, from a what has been a bruised and battered team. The Chairman has just bought 10,000 shares. Dividend provides strong underpin – we think it’s sustainable. Tate is yielding a juicy 5.5%. This is more or less covered by EastStarch proceeds in FY16. From FY17, it has to be funded organically and we have it 1.2x covered by cashflow. Tight but doable we think, in a climate of what should be rising profits & stable £:$ fx. Upgrading. Underlying momentum better than it looks. We upgrade FY16 by 4% and FY17 by 8% FY17 EPS growth is impacted by Europe exit reversal and a rising tax charge. Forecast 12% LFL EBIT growth is the truer measure of momentum for us.
TATE UPGRADE....... 27 Aug 2015 Tate & Lyle PLC TATE Jefferies International Buy 522.25 502.00 605.00 605.00 Upgrades SP TARGET 605p
<b>Insider Buying: Tate & Lyle PLC insider Purchases 10,000 Shares of Stock (TATE) August 25th, 2015</b> Tate & Lyle PLC (LON:TATE) insider Gershon,Peter purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were acquired at an average price of GBX 510 ($7.99) per share, for a total transaction of £51,000 ($79,912.25). The company also recently disclosed a dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, July 2nd were given a GBX 19.80 ($0.31) dividend. This represents a yield of 3.38%. The ex-dividend date of this dividend was Thursday, July 2nd. A number of research firms have recently weighed in on TATE. Numis Securities Ltd reaffirmed a “reduce” rating and set a GBX 545 ($8.54) price objective (down previously from GBX 563 ($8.82)) on shares of Tate & Lyle PLC in a research note on Tuesday, April 28th. Berenberg Bank lowered their target price on Tate & Lyle PLC from GBX 645 ($10.11) to GBX 625 ($9.79) and set a “hold” rating for the company in a report on Friday, May 29th. Liberum Capital restated a “sell” rating and issued a GBX 505 ($7.91) price objective on shares of Tate & Lyle PLC in a report on Friday, August 14th. Societe Generale upgraded Tate & Lyle PLC to a “buy” rating and set a GBX 620 ($9.71) price target for the company in a report on Thursday, July 30th. Finally, BNP Paribas cut their price objective on shares of Tate & Lyle PLC from GBX 550 ($8.62) to GBX 540 ($8.46) and set an “underperform” rating for the company in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of GBX 598.25 ($9.37). Tate & Lyle PLC (LON:TATE) traded up 0.89% during midday trading on Tuesday, hitting GBX 507.50. 1,909,139 shares of the stock were exchanged. The firm’s market capitalization is GBX 2.35 billion. The firm’s 50-day moving average price is GBX 525.15 and its 200 day moving average price is GBX 573.53. Tate & Lyle PLC has a 1-year low of GBX 501.18 and a 1-year high of GBX 744.50. Tate & Lyle PLC is a provider of ingredients and solutions to the food, beverage and other industries. The Company uses technology to turn raw materials into ingredients for its customers. These ingredients add taste, texture, nutrition and increased functionality to products. Its customers include industrial, animal feed, pharmaceutical and personal care markets. The Company operates in two segments namely Speciality Food Ingredients (LON:TATE) and Bulk Ingredients (BI). In SFI segment, the Company operates three categories: sweeteners, such as SPLENDA Sucralose and crystalline fructose;
Price has only just broken out of a large head and shoulders, projections of which are around 450p
Credit Suisse upgraded Tate & Lyle to 'neutral' from 'underperform' following the recent underperformance that has seen the shares fall below its price target. CS noted that the shares have de-rated to 15 times this year's estimated earnings and the dividend offers further support.
Another day, another fall in SP, does not surprise me anymore, the BOD do not seem to know what is happening. I see the final dividend is due soon, with shares going ex-dividend on 02.July, you would think the shares would rise in value, but with TATE anything is possible. I have also noted that just about every broker out there has downgraded these shares, they have do not believe the BOD are capable of turning this company around, meanwhile like Nero, the CEO fiddles while Rome burns. I am off to watch the Muppet show with my nephews/niece which does remind me of the BOD, which one would Javed Ahmed be, I wonder.
With a NAV of about £1 per share and a high PE TATE should be about 280p per share But I like them anyway so will wait for a good entry point.GL.